Collagen Patents (Class 530/356)
-
Patent number: 8785389Abstract: This invention relates to the production of biomaterials from polymeric collagen (PC) and its seeding with cells and other components of biomaterials. Polymeric collagen is isolated from tissue, suspended in an acidic solution, and then neutralized at low temperature. The neutralized suspension is then seeded with biomaterial components, such as cells, and the polymeric collagen aggregated to form a biomaterial comprising the biomaterial components. Polymeric collagen biomaterials produced as described herein may therefore be useful in a range of tissue engineering applications.Type: GrantFiled: July 16, 2010Date of Patent: July 22, 2014Assignee: UCL Business PLCInventors: Robert Brown, Burcak Alp, Hector Hadjipanayi
-
Patent number: 8784875Abstract: The invention relates to collagen for use in the treatment of inflammatory and degenerative skin diseases and damage to the skin connected therewith, such as in particular in the treatment of psoriasis, dermatitis, neurodermitis, rosacea, urticaria (hives), pruritus (itching), skin eczema and actinic keratosis. In particular, the invention relates to freeze-dried collagen in the form of layered dressings, sheets, pads or masks for the aforementioned use.Type: GrantFiled: November 29, 2011Date of Patent: July 22, 2014Assignee: MedSkin Solutions Dr. Suwelack AGInventors: Anja Kassner, Martin Trautmann, Sabine Gütt
-
Publication number: 20140193477Abstract: This disclosure relates to materials fabricated from collagen and uses relates thereto. Typically, layers of collagen are stretched during a curing period and optionally coated or impregnated with an elastin like protein. In certain embodiments, these materials can be used in tissue repair or arranged into cylinders and utilized as a prosthetic vascular graft.Type: ApplicationFiled: October 11, 2013Publication date: July 10, 2014Applicants: Emory University, Beth Israel Deaconess Medical Center, Inc.Inventors: Elliot Chaikof, Jeffrey Caves, Vivek Ashok Kumar, Adam W. Martinez
-
Publication number: 20140187743Abstract: The present invention relates to a membrane having bound thereto an antibacterial peptide that binds to collagen, and more particularly to a collagen membrane comprising a fusion peptide of a collagen-binding peptide and an antibacterial peptide, fixed to the collagen surface. The present invention provides a collagen membrane having surface activity by a fusion peptide bound to the surface thereof. When the collagen membrane is transplanted in vivo, the retention time of the fusion peptide in a local region can increase, and the fusion peptide can promote the cell migration, proliferation and differentiation associated with bone tissue regeneration, thereby maximizing the ability to regenerate bone tissue. Thus, the collagen membrane contributes to the development of therapeutic technology for bone induction and regeneration. Also, the fusion peptide may be applied to other types of graft materials made of collagen.Type: ApplicationFiled: December 16, 2011Publication date: July 3, 2014Applicant: Nano Intelligent Biomedical Engineering Corporation Co., Ltd.Inventors: Chong-Pyoung Chung, Yoon-Jeong Park, Jue-Yeon Lee, In Kyong Shim, Hyun Jung Park
-
Publication number: 20140187651Abstract: The present disclosure generally relates to collagen, and more particularly compositions and methods related to collagen-mimetic peptides. More specifically, the present disclosure provides a collagen-mimetic peptide and peptide systems comprising the amino acid sequence (Pro-Lys-Gly)4(Pro-Hyp-Gly)4(Asp-Hyp-Gly)4.Type: ApplicationFiled: February 10, 2014Publication date: July 3, 2014Applicant: WILLIAM MARSH RICE UNIVERSITYInventors: Jeffrey D. Hartgerink, Lesley R. O'Leary
-
Publication number: 20140179612Abstract: The present invention provides recombinant proteins comprising transferrin that is linked to tumstatin or other antiangiogenic protein and methods for producing and using the same. The present invention also provides an expression system, a plasmid, and a cell that is capable of expressing such recombinant proteins and methods for producing and using the same.Type: ApplicationFiled: August 15, 2012Publication date: June 26, 2014Applicant: The Regents of the University of Colorado, a body CorporateInventors: Uday B. Kompella, Robert I. Scheinman, Puneet Tyagi
-
Patent number: 8759487Abstract: A method of generating atelocollagen is disclosed. The method comprises contacting a human telopeptide-comprising collagen with a protease selected from the group consisting of neutrase, subtilisin, ficin recombinant human trypsin and recombinant human pepsin, wherein said human telopeptide-comprising collagen is expressed in a non-animal cell, thereby generating the atelocollagen. Compositions comprising the atelocollagen generated thereby are also disclosed.Type: GrantFiled: October 26, 2008Date of Patent: June 24, 2014Assignee: CollPlant Ltd.Inventors: Oded Shoseyov, Hanan Stein, Michal Rosenthal, Or Dgany, Tamar Haya Tal, Amit Yaari
-
Publication number: 20140170097Abstract: The invention provides compositions and methods for reversible covalent binding of benefit agents to keratinous substrates through the reaction of a dicarbonyl functional group on the surface of a benefit agent with reactive amines on keratinous surfaces. The deposits formed are durable and resistant to transfer, but are readily removed by contacting the deposit with an amine-containing solution.Type: ApplicationFiled: December 18, 2012Publication date: June 19, 2014Applicant: AVON PRODUCTS, INC.Inventors: Sung Bin Shin, Sen Yang
-
Publication number: 20140163205Abstract: The present disclosure provides synthetic collagen and methods of making and using synthetic collagen that include a synthetic collagen that facilitates wound closure comprising an isolated and purified triple helical backbone protein that facilitates wound closure comprising one or more alteration in a triple helical backbone protein sequence, that stabilize the isolated and purified triple helical backbone protein and does not disrupt an additional collagen ligand interaction; and one or more integrin binding motifs, wherein the isolated and purified triple helical backbone protein facilitates wound closure.Type: ApplicationFiled: December 3, 2013Publication date: June 12, 2014Applicant: THE TEXAS A&M UNIVERSITY SYSTEMInventors: Brooke H. Russell, Magnus Hook, Mariah S. Hahn, Elizabeth M. Cosgriff-Hernandez, Neungseon Seo, Marvin Xuejun Xu, Jose J. Rivera, Mary Beth Browning
-
Patent number: 8748579Abstract: Disclosed herein are a collagen-based matrix for use as a restorative material and a method for the preparation thereof. An atelocollagen dispersion is spread at a predetermined thickness over a plate and freeze-dried to form a porous collagen membrane. An atelocollagen dispersion is separately spread over a plate and pressurized to form a dense collagen membrane. This is overlaid with the porous collagen membrane and immersed in an EDS solution in ethanol to crosslink the two membranes with each other. From the bilayer structure thus constructed, EDS is removed, followed by lyophilization and cutting into an appropriate size.Type: GrantFiled: April 15, 2009Date of Patent: June 10, 2014Assignee: Dalim Tissen Inc.Inventors: Seong-Ki Lee, Si-Nae Park, Sang-Hee Bae
-
Patent number: 8747484Abstract: A method is disclosed for regenerating connective tissue by administering a scaffold comprising collagen fibers extracted from a soft coral. The length of the soft coral collagen fibers following stretching by about 15% is identical to the length of the fibers prior to stretching.Type: GrantFiled: July 18, 2013Date of Patent: June 10, 2014Assignees: Ramot at Tel-Aviv University Ltd., Technion Research & Development Foundation LimitedInventors: Yehuda Benayahu, Dafna Benayahu, Yoel Kashman, Amira Rudi, Yoram Lanir, Ido Sella, Einat Raz
-
Publication number: 20140154771Abstract: Disclosed herein is a structure having: a porous polymeric film permeated by a first extracellular matrix material; and a topcoat layer comprising a second extracellular matrix gel disposed on the film. Also disclosed herein is a method of: providing a porous polymeric film; permeating the film with a first extracellular matrix material; and applying a topcoat layer of a second extracellular matrix material to the film. Also disclosed herein is a method of: laser-machining holes through a film comprising collagen to form a web-like structure.Type: ApplicationFiled: February 11, 2014Publication date: June 5, 2014Applicant: The Government of the United States of America, as represented by the Secretary of the NavyInventors: Bradley R. Ringeisen, Russell Kirk Pirlo, Peter K. Wu
-
Patent number: 8742013Abstract: The present disclosure provides polymer compounds binding with lipoamide produced by the reaction of the primary amine group of lipoamide with the carboxy group of polysaccharide compounds such as chondroitin sulfates, carboxymethyl celluloses, or hyaluronic acids; functional compounds such as peptides, proteins, growth factors; or drugs; or biocompatible polymers such as poly(ethylene oxide), poly(vinyl alcohol), or poly(vinyl pyrrolidone). The present disclosure also provides their synthesis methods, products of hydrogels and films using the same as and methods for manufacturing the products.Type: GrantFiled: October 29, 2009Date of Patent: June 3, 2014Assignee: Seoul National University of Technology Center for Industrial CollaborationInventors: Insup Noh, Seongyeun Jo, Doyeon Kim, Junghoon Woo
-
Patent number: 8742091Abstract: Means for transferring efficiently a desired nucleic acid into a cell is provided. The present invention comprises using a complex comprising a collagen or a collagen derivative, and a desired nucleic acid.Type: GrantFiled: June 20, 2002Date of Patent: June 3, 2014Assignees: Dainippon Sumitomo Pharma Co., Ltd., Koken Co., Ltd., National Cancer CenterInventors: Masaaki Terada, Takahiro Ochiya, Yu Aso, Kimi Honma, Akihiko Sano, Shunji Nagahara
-
Patent number: 8742072Abstract: A biocompatible synthetic bone growth composition comprising a fibrillar collagen component and a calcium phosphate component. The composition is formed into particles, and then formed into a unitary article that may be provided at the site of a skeletal defect. An osteoinductive component may be further added, either before or after forming the unitary article. The composition may be formulated as a paste or putty and facilitates bone growth and/or repair.Type: GrantFiled: March 29, 2010Date of Patent: June 3, 2014Assignee: Zimmer Orthobiologics, Inc.Inventor: Kevin J. Thorne
-
Publication number: 20140147400Abstract: The present invention relates to the use of fish skin as novel industrial source of collagen. Advantageously, said skin is obtained after the filleting or cutting of the fresh fish and frozen immediately after filleting/cutting, thus guaranteeing a very good quality of the base material, both from the bacteriological standpoint and from the standpoint of the native property of the protein.Type: ApplicationFiled: January 31, 2014Publication date: May 29, 2014Inventors: Jamilah Bakar, Umi H. Razali, Dzulkifly M. Hashim, Awis Q. Sazili, Kaur Harvinder
-
Publication number: 20140142025Abstract: The disclosure describes collagen constructs comprising antimicrobial agents and related methods.Type: ApplicationFiled: March 15, 2013Publication date: May 22, 2014Applicant: MiMedx Group, Inc.Inventor: MiMedx Group, Inc.
-
Publication number: 20140142041Abstract: The disclosure describes collagen constructs comprising anticancer agents, preferably, platinum, and related methods.Type: ApplicationFiled: March 15, 2013Publication date: May 22, 2014Inventor: Thomas J. Koob
-
Patent number: 8722854Abstract: The present invention relates to degradation-stabilized, biocompatible collagen matrices which are distinguished in particular by the fact that they contain soluble collagen and peptide constituents, to processes for the preparation of such collagen matrices, which processes include in particular chemical crosslinking with an epoxy-functional crosslinking agent, and to the use of the collagen matrices according to the invention as a cosmetic or pharmaceutical agent, in particular for topical use, and as a wound treatment agent, as an implant or as a haemostatic agent in humans or animals, and as a scaffold for cell population in the biotechnology, basic research and tissue engineering field.Type: GrantFiled: December 19, 2011Date of Patent: May 13, 2014Assignee: MedSkin Solutions Dr. Suwelack AGInventors: Ralf Malessa, Anja Kassner
-
Publication number: 20140128573Abstract: An object is to provide a method for producing an ever-larger molecular weight collagen-like polypeptide single strand. Another object is to provide a method for controlling a molecular weight of a product to be obtained in desired magnitude upon producing a collagen-like polypeptide single strand. A solution is a method for producing a polypeptide including a step for allowing a condensation reaction of peptide oligomers represented by any one of formulas (1) to (3) (SEQ ID No:1 to SEQ ID No:3), wherein the condensation reaction is carried out in an aqueous solvent containing a phosphate ion in the range of 0 M to less than 0.01 M in the presence of a condensing agent, or a condensing agent and a condensing auxiliary: H-(Pro-Y-Gly)n-OH??(1); H-(Y-Gly-Pro)n-OH??(2); and H-(Gly-Pro-Y)n-OH??(3); wherein, in formulas (1) to (3), Y is hydroxyproline or proline, and n is an integer from 1 to 10.Type: ApplicationFiled: June 28, 2013Publication date: May 8, 2014Applicant: JNC CORPORATIONInventors: AKIHIRO UCHIDA, SHUJI SASAKI, AKIKO SHIMATANI, YOU UMEBAYASHI, KAZUSHI ISHIDA
-
Patent number: 8703908Abstract: A fusion protein of the invention comprises an immunoglobulin Fc region and a first target protein linked to the immunoglobulin Fc region. The first target protein comprises a collagen XVIII fragment, preferably endostatin. The immunoglobulin Fc region preferably comprises a hinge region, a CH2 region, and a CH3 region.Type: GrantFiled: June 26, 2012Date of Patent: April 22, 2014Assignee: Merck Patent GmbHInventors: Kin-Ming Lo, Yue Li, Stephen D. Gillies
-
Publication number: 20140107036Abstract: Improved methods are provided for the recombinant synthesis of collagen, particularly collagen VII, in host cell, and for therapeutic delivery of the same. The recombinant collagen is produced in a host cell that has increased levels of prolyl-4-hydroxylase, relative to basal cell levels. The collagen produced by the methods of the invention has increased numbers of modified proline residues, relative to a recombinant collagen produced in a host cell having basal levels of prolyl-4-hydroxylase. The increased proline modification provides for a collagen having increased stability, including increased in vivo stability.Type: ApplicationFiled: April 26, 2012Publication date: April 17, 2014Inventors: M. Peter Marinkovich, Alfred T. Lane, Jayakumar Rajadas
-
Publication number: 20140105856Abstract: System and methods for isolation of collagen and other fibrous tissue from adipose tissue are described herein. The method of the present invention isolates the collagen from adipose tissue by sonication. The tissue to be sonicated is placed in a container or a flow cell transparent to ultrasound waves. After sonication the sonicated material is filtered out through the bottom of the flow cell and the sonicated collagen is trapped in the filter, which may be taken for further processing. The isolated collagen can then be combined with a suitable carrier for re-injection to correct various tissue defects such as wrinkles, to form a carrier for the stem cells, a filler, and matrix for new collagen production by injecting into the desired area of the host.Type: ApplicationFiled: June 22, 2012Publication date: April 17, 2014Inventor: Stephen Schendel
-
Publication number: 20140107035Abstract: The present invention has demonstrated for the first time that orally administered type I collagen (CI) induced tolerance to CI in patients suffering from systemic sclerosis (SSc) and ameliorated clinical manifestations of the disease. Accordingly, the present invention provides methods of treating a fibrosing disease by oral administration of a tissue protein, for example, collagen, derived from the tissue undergoing fibrosis.Type: ApplicationFiled: December 13, 2013Publication date: April 17, 2014Applicant: The University of Tennessee Research FoundationInventors: Arnold E. Postlethwaite, Andrew H. Kang
-
Patent number: 8691951Abstract: It is an object of the present invention to provide a Type I-Type IV collagen hybrid gel, which maintains characteristics of a Type IV collagen and is superior in gel strength. It is the Type I-Type IV collagen hybrid gel obtained by mixing 100 to 500 parts by mass of the Type I collagen having fibrosis ability, relative to 100 parts by mass of the Type IV collagen having gelling ability. A three-dimensional structure is formed, where a membrane-like substance by the Type IV collagen is formed onto a fibrous substance by the Type I collagen, so as to be able to provide cell culture environment approximate to a basement membrane of a living body.Type: GrantFiled: February 14, 2011Date of Patent: April 8, 2014Assignees: Japan Institute of Leather Research, Osaka UniversityInventors: Shunji Hattori, Yoh-ichi Koyama, Hitomi Fujisaki, Kiyotoshi Sekiguchi, Sugiko Futaki, Ryoko Sato
-
Publication number: 20140093912Abstract: A method of preparing a crosslinked, collagen-based medical scaffold is provided, comprising: (a) immersing a sample of fibrous and/or non-fibrous collagen in a buffered acidic, aqueous solution comprising an alcohol; (b) contacting the collagen in solution with a catalytic component comprising 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride for a time at least sufficient to effect reaction between amino and carboxyl groups present on the collagen and to yield crosslinked collagen that is resistant to pronase degradation; and (c) drying the crosslinked collagen to yield a porous, crosslinked collagen article wherein the porous, crosslinked collagen article demonstrates a pore size of 10-500 microns. Also provided are bioactive collagen medical scaffolds for wound care dressings, hernia repair prosthetics, and surgical incision closure members, prepared using the method above.Type: ApplicationFiled: September 30, 2013Publication date: April 3, 2014Inventors: Ali HUSSAIN, Patrick Cahalan, Linda Cahalan
-
Publication number: 20140094590Abstract: It is an object of the present invention to provide a protein having high cellular adhesiveness that is useful as a cell adhesion support. The present invention provides a cell-adhesive protein comprising methionine, wherein at least a portion of the methionine residues is oxidized.Type: ApplicationFiled: September 27, 2013Publication date: April 3, 2014Applicant: Fujifilm CorporationInventor: Kazutaka OGIWARA
-
Patent number: 8686117Abstract: A platelet aggregation inducing substance containing as an active ingredient a polypeptide having a peptide fragment represented by formula (1) (component A): -(Pro-X-Gly)n-??(1) wherein X represents Pro or Hyp; and n represents an integer of from 20 to 5,000.Type: GrantFiled: December 12, 2007Date of Patent: April 1, 2014Assignee: JNC CorporationInventors: Yasuto Umeda, Shinichi Takasaki, Takafumi Takebayashi, Takahiro Kawai
-
Publication number: 20140079753Abstract: Compositions and methods for tissue repair are provided including cell binding peptides and BMP binding peptides. The cell binding peptides bind to one or more of stem cells and fibroblasts. The tissue for repair includes bone, tendon, muscle, connective tissue, ligament, cardiac tissue, bladder tissue, or dermis. Implantable devices for tissue repair are provided to which the cell and/or BMP binding peptides are attached, such as acellular extracellular matrix having attached binding peptide and bone graft material comprising a ceramic.Type: ApplicationFiled: November 18, 2013Publication date: March 20, 2014Applicant: Affinergy, LLCInventors: Martyn Kerry Darby, Dalia Isolda Juzumiene, Isaac Gilliam Sanford, Jonathan Allen Hodges, Shrikumar Ambujakshan Nair
-
Publication number: 20140072747Abstract: A biocompatible, resorbable biphasic collagen membrane having a first area of relatively higher tensile strength and stiffness and lower porosity and a second area of relatively lower tensile strength and stiffness and higher porosity, and a method of manufacturing the such a membrane.Type: ApplicationFiled: November 15, 2013Publication date: March 13, 2014Applicant: Osseous Technologies of AmericaInventors: DAVID CHEUNG, WILLIAM KNOX, JAY MALMQUIST, EDWIN SHORS, DENNIS SMILER
-
Publication number: 20140066379Abstract: A recombinant vector, transgenic fish egg using the same and biomaterial using the same are applied to provide a transgenic fish that secreting recombinant human procollagens or collagens, and further to provide the biomaterial having the recombinant human procollagens or collagens and extract the recombinant human procollagens or collagens from the part(s), having the recombinant human procollagens or collagens, of the transgenic fish.Type: ApplicationFiled: August 28, 2013Publication date: March 6, 2014Applicant: Body Organ Biomedical Corp.Inventors: Chuian-Fu Ken, Hong-Yi Gong, Jen-Leih Wu, Horng-Ji Lai, Chien-Cheng Lin, Yong-Guei Chen, Cheng-Hung Chou
-
Publication number: 20140044948Abstract: The object of the present invention is to provide a collagen fiber membrane, which has sufficient strength and can be used as a cell culture substrate, a scaffold material for regenerative medicine (for example, material for tissue engineering of cartilage, bone, ligament, corneal stroma, skin, or liver), an implantation material (for example, wound dressing material, bone grafting material, hemostatic material, anti-adhesive material) or a carrier for drug delivery. The object of the present invention can be solved by a fish-derived collagen fiber membrane, characterized in that (1) a tensile strength is 30 MPa or more, (2) a density determined by the gravimetric method, is 0.4 g/cm3 or more, and (3) an average membrane thickness is 1 ?m to 2 mm, and a variation in membrane thickness is plus or minus 30%, relative to the average membrane thickness.Type: ApplicationFiled: November 28, 2011Publication date: February 13, 2014Applicant: Tokyo Institute of TechnologyInventors: Junzo Tanaka, Toshiyuki Ikoma, Tomohiko Yoshioka
-
Publication number: 20140041547Abstract: Biocompatible phase invertible proteinaceous compositions and methods for making and using the same are provided. Phase invertible compositions in accordance with the invention are prepared by combining a liquid proteinaceous substrate and a liquid crosslinking composition, where the liquid crosslinking composition includes a macromolecular crosslinking agent. Also provided are kits for use in preparing the subject compositions. The subject compositions, kits and systems find use in a variety of different applications.Type: ApplicationFiled: October 16, 2013Publication date: February 13, 2014Applicant: Tenaxis Medical, Inc.Inventors: Ronald Dieck, Ian J. Handley, Neil Winterbottom, Joanna Wang
-
Patent number: 8642735Abstract: The invention provides composition and methods for repairing a ruptured anterior cruciate ligament.Type: GrantFiled: April 18, 2012Date of Patent: February 4, 2014Assignee: Children's Medical Center CorporationInventors: Martha M. Murray, Michael F. Murray, Jennifer Marler
-
Publication number: 20140031526Abstract: The present invention relates to methods for generation of high molecular ordered fibrilar structures. More particularly, the method of the invention utilizes CBD's (cellulose binding domain) ability to form dimers for directing ordered assembly of fibrous proteins such as silk proteins into super-molecular fibrilar structures. The invention further provides fibrilar structures such as fibers and articles comprising said fibrilar structures.Type: ApplicationFiled: February 2, 2012Publication date: January 30, 2014Applicant: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.Inventors: Oded Shoseyov, Shaul Lapidot, Sigal Meirovitch
-
Patent number: 8633299Abstract: This invention includes malleable, biodegradable, fibrous compositions for application to a tissue site in order to promote or facilitate new tissue growth. One aspect of this invention is a fibrous component that provides unique mechanical and physical properties. The invention may be created by providing a vessel containing a slurry, said slurry comprising a plurality of natural or synthetic polymer fibers and at least one suspension fluid, wherein the polymer fibers are substantially evenly dispersed and randomly oriented throughout the volume of the suspension fluid; applying a force, e.g., centrifugal, to said vessel containing said slurry, whereupon said force serves to cause said polymer fibers to migrate through the suspension fluid and amass at a furthest extent of the vessel, forming a polymer material, with said polymer material comprising polymer fibers of sufficient length and sufficiently viscous, interlaced, or interlocked to retard dissociation of said polymer fibers.Type: GrantFiled: May 25, 2012Date of Patent: January 21, 2014Assignee: Kensey Nash BVF Technology LLCInventors: Timothy A. Ringeisen, W. Christian Wattengel, Emme M. Castiglione-Dodd
-
Patent number: 8628572Abstract: Provided herein is an endothelial scaffold comprising, consisting of, or consisting essentially of decellularized corneal stroma. In some embodiments, the scaffold has cultured endothelial cells seeded thereon. Methods of treating a patient in need of corneal endothelial transplant are also provided, including implanting the scaffold as described herein onto a cornea of the patient (e.g., by deep keratectomy).Type: GrantFiled: February 25, 2010Date of Patent: January 14, 2014Assignee: Wake Forest University Health SciencesInventors: Shay Soker, J. Koudy Williams, Patrick Laber, Margaret Greven, Keith A. Walter
-
Patent number: 8628593Abstract: The process described in the instant invention has the steps of dissolving the lipid-containing biomass in an ionic liquid, whereby a lipid phase and a hydrophilic phase are formed. The lipid phase contains primarily triglycerides, which can be converted to biodiesel by transesterification to, e.g., methyl esters. The hydrophilic phase comprises dissolved biopolymers, such as cellulose, hemicellulose, and protein. The biopolymers are converted in situ to compounds that are insoluble in the molten inorganic salt hydrate. The molten inorganic salt hydrates regenerated by removing insolubles, such as lignin, ash from the biomass, and water.Type: GrantFiled: February 18, 2011Date of Patent: January 14, 2014Assignee: BOleCON International Holding N.V.Inventors: Jacob A. Moulijn, Sjoerd Daamen, Paul O'Connor, Rob Van Der Meij
-
Publication number: 20140011980Abstract: Method for sterilizing a hydrogel composition include subjecting the composition to pulsed light comprising broadband spectrum radiation, the pulsed light being at a dose effective to sterilize the composition without causing significant change in rheology of the composition.Type: ApplicationFiled: July 3, 2013Publication date: January 9, 2014Inventors: Kaustubh S. Chitre, Xiaojie Yu, Nicholas J. Manesis
-
Publication number: 20130344165Abstract: This disclosure relates to compounds and compositions for forming bone and methods related thereto. In certain embodiments, the disclosure relates to methods of forming bone comprising implanting a bone graft composition comprising a growth factor such as BMP in a subject at a site of desired bone growth or enhancement in combination with a JAB1 blocker.Type: ApplicationFiled: February 23, 2012Publication date: December 26, 2013Applicant: EMORY UNIVERSITYInventors: Scott D. Boden, Sreedhara Sangadala
-
Publication number: 20130337149Abstract: A material derived from sea cucumber collagen fibrils is suitable for use in corneal replacements or as an implantable contact lens. To produce material, the collagen fibrils are centrifuged into orthogonal stacks of lamellae comprised of aligned fibrils. The resulting structure is a transparent film of arbitrary thickness very similar in structure to mammalian corneal tissue.Type: ApplicationFiled: August 20, 2013Publication date: December 19, 2013Applicants: Shriners Hospitals for Children, University of South FloridaInventors: W. Garrett Matthews, August Heim, Thomas J. Koob
-
Publication number: 20130337227Abstract: The object of the present invention is to provide a non-fibrogenesis collagen material which has a sufficient strength and can be used as a cell culture substrate, a scaffold material for regenerative medicine (for example, material for tissue engineering of cartilage, bone, ligament, corneal stroma, skin, or liver), an implantation material (for example, wound dressing material, bone grafting material, hemostatic material, anti-adhesive material) or a carrier for drug delivery. The object of the present invention can be solved by a non-fibrogenesis collagen material characterized by comprising a fish-derived collagen.Type: ApplicationFiled: November 28, 2011Publication date: December 19, 2013Applicant: Tokyo Institute of TechnologyInventors: Junzo Tanaka, Toshiyuki Ikoma, Tomohiko Yoshioka
-
Publication number: 20130330417Abstract: Nanocellulose foams containing at least one active ingredient and methods of preparing such nanocellulose foams containing one or more active ingredients are provided herein. In some embodiments, a method for preparing nanocellulose foam containing active ingredients may include forming a liquid mixture of nanocellulose, wherein the nanocellulose is at least one of dispersed, suspended or gelled in the liquid mixture; drying the liquid mixture of nanocellulose to form a nanocellulose foam; and mixing at least one active ingredient into at least one of the liquid mixture of nanocellulose or the nanocellulose foam. In some embodiments, a nanocellulose structure may include a nanocellulose foam comprising at least one of a carboxylate group, a hydroxyl group, or a sulfate group bonded to an active ingredient. In some embodiments, the nanocellulose structures are enhanced or crosslinked with metal cations.Type: ApplicationFiled: June 7, 2013Publication date: December 12, 2013Inventors: Hong Dong, James F. Snyder
-
Publication number: 20130324473Abstract: The invention relates to the preparation and provision of a gelling collagen composition that instantaneously forms a collagen matrix, and means for the preparation and use thereof, in particular as part of a therapeutic treatment.Type: ApplicationFiled: January 26, 2012Publication date: December 5, 2013Applicant: AMEDRIX GmbHInventor: Thomas Graeve
-
Publication number: 20130323199Abstract: A collagen material is characterized in being constituted of collagen gel fragments. Furthermore, the collagen gel fragments may have an orientation. A method for producing a collagen material is characterized in comprising a step for preparing collagen gel fragments, a step for arranging the collagen gel fragments in a desired shape, and a step for drying the collagen gel fragments arranged in the desired shape. Moreover, in one embodiment of the method for producing a collagen material a step may include imparting an orientation to the collagen gel fragments.Type: ApplicationFiled: February 20, 2012Publication date: December 5, 2013Applicant: Atree, Inc.Inventors: Taro Saku, Yoshihiro Isobe, Takaoki Isobe
-
Publication number: 20130310539Abstract: The present invention relates to a method to treat a grafts, implant, scaffold, and constructs, including allografts, xenografts, autografts, and prosthetics comprising collagen, with an inhibitor of collagen cross-links and/or advanced glycation endproducts (AGE), in order to alleviate the mechanical weakness induced by the cross-links The invention also provides for kits for use in the operating theater during autograft, allograft or xenograft procedures, or for preparing allograft, xenografts or prosthetics that have not been already treated prior to packaging. The kit comprises a first agent or agents that inhibit collagen cross-links and/or advanced glycation endproducts, instructions for use, optionally a wash or rinse agent, and a device for containing the graft and first agent.Type: ApplicationFiled: May 16, 2013Publication date: November 21, 2013Inventors: Jonathan W. Bourne, Peter A. Torzilli
-
Publication number: 20130310540Abstract: An object of the present invention is to obtain a useful extract from aquatic animal tissues. The present invention provides a fish cartilage water extract containing a proteoglycan having a molecular weight of not less than 2,500,000 (250×104). The extract has a superior skin anti-aging effect (in particular, anti-inflammatory effect, skin barrier functionality improving effect, and skin water-retention ability improving effect). Moreover, the fish cartilage water extract of the present invention provides these effects not only through application to skin but also through oral administration.Type: ApplicationFiled: January 19, 2012Publication date: November 21, 2013Applicants: SUNSTAR INC., HIROSAKI UNIVERSITYInventors: Yoji Kato, Yohtaro Katagata, Masashi Goto, Kazushi Yamamoto, Mariko Maeda, Yukako Hanada, Motoko Takai, Yutaka Suekawa
-
Patent number: 8586345Abstract: The invention is directed to formation and use of electroprocessed collagen, including use as an extracellular matrix and, together with cells, its use in forming engineered tissue. The engineered tissue can include the synthetic manufacture of specific organs or tissues which may be implanted into a recipient. The electroprocessed collagen may also be combined with other molecules in order to deliver substances to the site of application or implantation of the electroprocessed collagen. The collagen or collagen/cell suspension is electrodeposited onto a substrate to form tissues and organs.Type: GrantFiled: March 21, 2011Date of Patent: November 19, 2013Assignee: Virginia Commonwealth University Intellectual Property FoundationInventors: David G. Simpson, Gary L. Bowlin, Gary E. Wnek, Peter J. Stevens, Marcus E. Carr, Jamil A. Matthews, Saravanamoorthy Rajendran
-
Publication number: 20130302895Abstract: An isolated collagen fiber is disclosed, wherein a length of the fiber prior to stretching by about 15%, is identical to a length of the fiber following said stretching by about 15%. The fiber comprises a Nuclear Magnetic Resonance (NMR) spectroscopic profile as shown in FIG. 1. Uses thereof and method of isolating are also disclosed.Type: ApplicationFiled: July 18, 2013Publication date: November 14, 2013Inventors: Yehuda BENAYAHU, Dafna BENAYAHU, Yoel KASHMAN, Amira RUDI, Yoram LANIR, Ido SELLA, Einat RAZ
-
Publication number: 20130296527Abstract: The invention relates to novel curcumin and tetrahydrocurcumin derivatives, which have been modified at one phenolic group to incorporate more-reactive groups. The curcumin and tetrahydrocurcumin derivatives are in the form of monomers, dimmers, and polymers.Type: ApplicationFiled: July 15, 2013Publication date: November 7, 2013Applicant: Research Foundation of the City University of New YorkInventors: Krishnaswami Raja, Probal Banerjee, Andrew Auerbach, Wei Shi, William L'Amoreaux